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A SYSTEMATIC REVIEW OF THE DISEASE-SPECIFIC AND THE
GENERIC QUALITY-OF-LIFE INSTRUMENTS IN CONGESTIVE
HEART FAILURE
Gu NY1, Gwadry-Sridhar F2
1University of Southern California, Los Angeles, CA, USA, 2University
of Western Ontario, and London Health Sciences Centre, London,
ON, Canada
OBJECTIVE: There is increasing interest in minimizing respon-
der burden when eliciting health related quality-of-life (HRQoL).
We conducted a systematic review of measurement properties of
two HRQoL instruments: the disease-speciﬁc questionnaire, the
Minnesota Living with Heart Failure questionnaire (MLHFQ)
and the generic questionnaire, (SF-36), in congestive heart failure
(CHF). METHODS: We searched MEDLINE, PubMed, Google
Scholar, American Heart Association and Texas Heart Institute.
Using MESH terms: Minnesota living with heart failure,
MLHFQ, SF-36 and chronic heart failure questionnaire. We
included studies that used SF-36 with MLHFQ. Studies had to
be published in English between 1980 and 2005. We assessed the
following properties: reliability (Cronbach’s alpha, and Pearson’s
correlation), construct validity (longitudinal correlations) using
multi-trait, multi-method matrix (MTMM), within and between
domains for subscales and summary scores and responsiveness
(effect size). RESULTS: Our search rendered 28 references, 15
papers (11 trials and 4 reviews). All except one study revealed
consistent outcome measures in domain correlation, regardless
of whether subscales or summary scores were used. The Cron-
bach’s alpha for the MLHFQ were above 0.8, and ranged from
0.78 to 0.93 for the SF-36. The Pearson’s correlations exhibit
that the emotional domains between the two instruments demon-
strate much lower correlations (ranged from 0.409 to 0.52) com-
pared to that of their physical domains (ranged from 0.54 to
0.72). The effect sizes for the emotional domains, especially for
the SF-36, were lower than that of physical domain. Similar ﬁnd-
ings were also found in using MTMM approach. At the same
time, signiﬁcant correlation between the MLHFQ physical and
the emotional domains found in one study warrants close 
examination. CONCLUSIONS: The measurement properties
MLFHQ and SF-36 in CHF are well documented as independent
measures, however concurrent use illustrated inconsistencies
between similar domains giving one reason to pause when con-
sidering mapping from one instrument to the other.
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PREDICTORS OF HIGH BLOOD PRESSURE KNOWLEDGE IN
HYPERTENSIVE PATIENTS
Gu A1, Shaya FT1, Saunders E2
1University of Maryland School of Pharmacy, Baltimore, MD, USA,
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OBJECTIVES: Patient knowledge of the risks for hypertension
greatly affects the extent to which population-based primary pre-
ventive strategies can be successfully implemented. The objective
of this study is to assess the determinants of knowledge of the
risks for hypertension in an urban, predominantly African-Amer-
ican hypertensive population. METHODS: Using a 12-item high
blood pressure knowledge questionnaire, patient knowledge in
hypertension was measured at patient enrollment. Predictors of
knowledge include age, race, severity of hypertension gender and
current smoking status. The percentage of correct responses was
calculated for the overall group, and for subgroups deﬁned by
independent variables. We used multiple regression to assess the
effects of independent variables on the knowledge of hyperten-
sion. RESULTS: Out of 125 patients, most are African 
American (82.9%), female (66.7%), younger than 65 years
(72.0%), nonsmoker (82.3%) and with pre-hypertension
(70.4%). The overall mean blood pressure knowledge score was
81.5%, with the range of 0–100%. There were subgroup differ-
ences in the scores with signiﬁcant associations between high
blood pressure knowledge score and hypertension severity and
smoking status. When controlling for other variables, patients
with systolic blood pressure (SBP) higher than 140mmHg were
more likely to have lower scores (p = 0.08), while nonsmokers
tended to have higher score than smokers (p = 0.05). CON-
CLUSIONS: Patients with hypertension exhibit a high level of
high blood pressure knowledge. Lower SBP and non-smoking
status signiﬁcantly predict greater knowledge.
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BENEFICIAL IMPACT ON BLOOD PRESSURE CONTROL
AMONG MEN PRESCRIBED SILDENAFIL CITRATE
Scranton R1, Lawler E1, Gagnon D1, Gaziano J1, Botteman MF2,
Harnett J3
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OBJECTIVES: We evaluated whether pharmacological treat-
ment for erectile dysfunction (ED) had a beneﬁcial change in the
control of blood pressure among men being treated for hyper-
tension in the New England VA Healthcare System (VISN 1).
METHODS: We retrospectively analyzed medical record data
from VISN 1 patients diagnosed with hypertension receiving a
prescription for ED before February 1, 2003 and had at least one
blood pressure measurement before after treatment for ED after
excluding subjects with congestive heart failure, cancer, renal
failure, liver disease, or pulmonary hypertension. We modeled
changes in systolic blood pressure (SBP) and various clinical vari-
ables over a 4 year period using a linear mixed model both
overall and stratiﬁed by baseline SBP. RESULTS: We assessed
6768 men with an average age of 61.6 ± 9.92 prescribed almost
exclusively sildenaﬁl who had 148,997 blood pressure measure-
ments. SBP was signiﬁcantly reduced (“C17.84 and -5.53; both
P < 0.0001) in those with baseline SBP >160 and >140 to °Ü 
160mmHg blood pressure groups. There was no appreciable
change in BP for those with baseline SBP of <140. Likely clini-
cal variables to explain these changes increased after treatment
for ED such as starting blood pressure medications (p < 0.0001)
or greater intensity of blood pressure surveillance as indicated
by more blood pressure measures. CONCLUSIONS: This is the
ﬁrst study of this magnitude using analytical methods enabling
the assessment of thousands of blood pressure measures in order
to demonstrate a favorable association between receiving treat-
ment of a therapy targeted at improving quality of life and its
collateral affect on management of a chronic disease. In this
study limited mostly to men prescribed sildenaﬁl, those with ele-
vated blood pressure experienced dramatic improvements in
blood pressure that appear to be related to increases in clinically
relevant behaviors such as initiation of blood pressure treatment.
EAR—Health Care Use & Policy
PER1
ECONOMIC EVALUATION OF STRATEGIES FOR SCREENING
NEWBORNS FOR BILATERAL HEARING IMPAIRMENT IN
FRANCE
Barré S, Corbillon E
Haute Autorité de Santé, Saint Denis La Plaine, France
OBJECTIVES: To compare the cost-effectiveness of 3 screening
strategies in France (birth cohort of 800,000 children) as evi-
dence for universal screening is scarce because available tests
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have low positive predictive value, need further development,
and costs and consequences of screening are not fully known.
METHODS: We entered economic/clinical data and expert
opinion into a clinical decision model in order to compare: 1).
Targeted screening (TS) of children with one or more risk factors
for hearing disorders; 2). Universal neonatal hearing screening
(UNHS) by automated auditory brainstem response (AABR);
and 3). UNHS by otoacoustic emission (OAE) testing. RESULTS:
1). TS detected fewer than 15% of cases of bilateral hearing
impairment; 2). AABR-based UNHS was the most efﬁcient but
also costly strategy; and 3). OAE-based UNHS gave a higher
number of false positives than strategy two did. Results were sen-
sitive to prevalence, lost-to-follow-up rates, and costs. CON-
CLUSIONS: About 1 to 3 children/1000 in France are born with
at least moderate bilateral hearing impairment which should be
detected and treated early for normal development (speech, cog-
nitive and social functions). Our results for France conﬁrm pub-
lished data for other countries and can help our decision-makers
prioritize screening strategies. However, longer term dynamic
modeling is needed.
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OUTCOMES ASSOCIATED WITH AN OTITIS PARENT
QUESTIONNAIRE IN PEDIATRIC PATIENTS WITH ACUTE
OTITIS MEDIA FOLLOWING ADMINISTRATION OF CEFDINIR
ORAL SUSPENSION OR HIGH DOSE
AMOXICILLIN/CLAVULANATE ORAL SUSPENSION
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OBJECTIVES: To compare parent-reported outcomes for chil-
dren receiving either cefdinir (Omnicef®) or amoxicillin/clavu-
lanate (Augmentin ES-600®) oral suspensions for the treatment
of acute otitis media. Outcomes of satisfaction, tolerability, com-
pliance and work/daycare missed were assessed using the Otitis
Parent Questionnaire (OPQ). METHODS: In a phase 4, single-
blind, parallel-group, randomized, multi-center study designed
to compare safety and efﬁcacy of cefdinir oral suspension (7
mg/kg/day every 12 hours for 10 days) to amoxicillin/clavulanate
oral suspension (90/6.4mg/kg/day amoxicillin base every 12
hours for 10 days), parents or legally authorized representatives
of patients were asked to complete the OPQ, 12–15 days after
the ﬁrst dose of treatment. RESULTS: The intent-to-treat popu-
lation included 311 patients, with a mean age of 37 months.
Parents reported signiﬁcantly better ease of use and taste in the
cefdinir vs. the amoxicillin/clavulanate treatment groups (both 
p < 0.0001); parents were satisﬁed or very satisﬁed with the ease
of use (89%) and with the taste of cefdinir (85%) as compared
with amoxicillin/clavulanate (57% and 39%, respectively). Chil-
dren were more likely to take their medication in the cefdinir
group compared to the amoxicillin/clavulanate group: parents
reported 82% of children took at least 95% of their doses of cef-
dinir, while 61% took at least 95% of the prescribed dose of
amoxicillin/clavulanate (p < 0.0001). Parent reported data sug-
gested that their children were signiﬁcantly more likely to expe-
rience diarrhea/loose stools in the amoxicillin/clavulanate group
than in the cefdinir group (28% vs. 18%; p = 0.0341). There
were no statistically signiﬁcant differences in work/daycare
missed. CONCLUSIONS: Based on parents’ assessments using
the OPQ, cefdinir was easier to administer and better tasting.
Children who received cefdinir experienced less vomiting and
diarrhea/loose stools. In addition, these children were reported
to be more compliant than those who received amoxicillin/
clavulanate.
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PREVALENCE OF INTRAOCULAR HYPERTENSION AND
GLAUCOMA IN AN UNSELECTED FRENCH POPULATION
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OBJECTIVES: In France, the prevalence of primary open angle
glaucoma has been estimated at 2% of the population over 40
years old. Given the limited data available, we prompted an epi-
demiological survey on the prevalence of ocular hypertension
and high pressure glaucoma in France. The principal objective
of this survey was to evaluate the prevalence of ocular hyper-
tension and high pressure glaucoma in subjects who were vol-
unteers for a health assessment, and to ﬁnd some risk factors.
METHOD: Clinical and laboratory data were collected during
the screening program, as well as information on the way of life,
and the personal and family medical history. All volunteers were
subjected to an intra ocular pressure, IOP recording with an air
tonometer. Those with an IOP above 21 mm Hg underwent a
FDT (frequence dubling technology) visual ﬁeld and a non
stereoscopic photograph with a digital non mydriatic camera.
Among 2797 subjects, 2165 subjects (i.e. 77.4%) agreed to par-
ticipate. Altogether, 2074 subjects (1384 men and 690 women)
were included in the study. RESULTS: Intraocular pressure >21
mmHg was observed in 10.1% of men and 6.4% of women. This
prevalence increased with age. Glaucoma was conﬁrmed in 2.2%
of men and in 3.0% of women. Prevalence of glaucoma in men
varied between 0.8% in the youngest subjects and 5.7% in sub-
jects over 60 years, and between 0.6% and 4.7%, respectively
in women. Logistic regression demonstrated that few parameters
of the health assessment could be linked to intraocular pressure
or glaucoma. CONCLUSION: This cross sectional study demon-
strated that there is a higher prevalence of ocular hypertension
and high pressure glaucoma than reported in currently published
data. This study did not reveal any major factors that could be
linked to ocular hypertension and glaucoma.
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PREVALENCE AND DESCRIPTION OF TREATMENT WITH
INTRAOCULAR PRESSURE LOWERING TOPICAL
MEDICATIONS IN CONTINENTAL FRANCE
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OBJECTIVES: The objective of the present study is to estimate
the prevalence of treatment with intraocular pressure (IOP) low-
ering topical medication in subjects aged 40 years or more in
continental France, and to describe the type of therapy, the com-
pliance and quality of life of the treated subjects. METHODS:
This is a telephone survey performed in general population on a
representative sample of 5726 subjects during the year 2004.
Subjects treated for glaucoma or HTO were deﬁned as those:
declaring using eye drops for more than one month and 1) citing
one of the 52 registered IOP-lowering topical medications,
and/or 2) declaring that they were taking the eye drops for glau-
coma or ocular hypertension (OHT). Quality of life was 
measured using the GlauQOL-17 questionnaire. RESULTS:
Globally, 237 subjects (4.1%) corresponded to this deﬁnition.
The prevalence increased with age, from 0.7% in subjects aged
40–44 years to 10.6% in those aged 80 years or more. 
Beta-blockers (49.5%) and prostaglandins (37.4%) were the
more frequent treatments, followed by carbonic anhydrase
inhibitors (15.3%), sympathomimetic mydriatics (5.7%) and
myotics (1.3%). Compliance was not total for 39% of the
